Even as the novel coronavirus has derailed daily life and business operations, the life sciences sector continues to see companies make public debuts and ink both financing and partnership deals.
In venture capital, US deal activity in the first quarter tallied 2,300 financings totaling $34.2 billion, according to the latest report by the National Venture Capital Association, which uses data from PitchBook. That’s roughly on track to match the total raised in the past two years, both record-setters in one way or another. But the likelihood of that pace continuing is slim, according to the report.
Image: Sarah de Crescenzo
{iframe}https://xconomy.com/national/2020/04/23/life-science-a-vc-bright-spot-in-q1-but-startups-may-soon-struggle/?utm_source=Xconomy&utm_campaign=db66962cef-NEWSLETTER_all_stories&utm_medium=email&utm_term=0_2aa91c0bc9-db66962cef-288460969&mc_cid=db66962cef&mc_eid=7fe06a878f{/iframe}